首页> 美国卫生研究院文献>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease >Inhibition of 5‐Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β‐Arrestin2–Mammalian Target of Rapamycin/p70S6K Pathway
【2h】

Inhibition of 5‐Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β‐Arrestin2–Mammalian Target of Rapamycin/p70S6K Pathway

机译:抑制5-羟色胺受体2B可减少血管再狭窄并减轻雷帕霉素/ p70S6K途径的β-Arrestin2-哺乳动物靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAs a monoamine neurotransmitter, 5‐hydroxytryptamine (5‐HT) or serotonin modulates mood, appetite, and sleep. Besides, 5‐HT also has important peripheral functions. 5‐HT receptor 2B (5‐HT2BR) plays a key role in cardiovascular diseases, such as pulmonary arterial hypertension and cardiac valve disease. Percutaneous intervention has been used to restore blood flow in occlusive vascular disease. However, restenosis remains a significant problem. Herein, we investigated the role of 5‐HT2BR in neointimal hyperplasia, a key pathological process in restenosis.
机译:背景作为单胺类神经递质,5-羟色胺(5-HT)或血清素可调节情绪,食欲和睡眠。此外,5‐HT还具有重要的外围功能。 5‐HT受体2B(5‐HT2BR)在心血管疾病如肺动脉高压和心脏瓣膜疾病中起关键作用。经皮介入已被用于恢复闭塞性血管疾病中的血流。然而,再狭窄仍然是一个重大问题。本文中,我们研究了5-HT2BR在新内膜增生中的作用,新内膜增生是再狭窄的关键病理过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号